Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach

  • End date
    Dec 15, 2025
  • participants needed
  • sponsor
    Peking University
Updated on 15 May 2021


Gastric cancer is a highly heterogeneous tumor. The most commonly used clinical classifications of gastric cancer are Lauren classification (intestinal, diffuse, mixed) and World Health Organization(WHO) classification (papillary adenocarcinoma, tubular adenocarcinoma, mucinous glands cancer and low-adhesion cancer). Hepatoid adenocarcinoma of the stomach (HAS) is a special and rare type of gastric cancer.

Compared with ordinary gastric cancer, HAS has unique clinicopathological characteristics, prone to liver metastasis and lymph node metastasis, has a highly aggressive and malignant biological behavior, a worse prognosis than alpha fetoprotein(AFP) normal gastric cancer, and is easily confused with hepatocellular carcinoma(HCC). There is the possibility of misdiagnosis and mistreatment, so it has gradually attracted people's attention. Most of the domestic and foreign literature on HAS in the past 30 years are retrospective cases or small sample reports, and there are few prospective studies. There is no standard treatment plan for HAS. The main treatment is based on gastric adenocarcinoma. The clinical treatment principle is a comprehensive treatment plan with surgical resection as the mainstay, supplemented by systemic chemotherapy and local interventional therapy. This type of gastric cancer has a relatively high degree of malignancy, rapid progress of the disease, and easy recurrence after surgery. There is no standard treatment plan in China and other foreign countries.

The aim of this study was to evaluate the efficacy and safety of apatinib with oxaliplatin and S-1 treatment advanced hepatoid adenocarcinoma of the stomach.

Condition Gastropathy, Stomach Discomfort, Gastric Cancer, Gastric Cancer, Stomach Cancer, Stomach Discomfort, Gastric Carcinoma, Stomach Cancer, gastric cancers, Hepatoid Adenocarcinoma of The Stomach
Treatment Oxaliplatin, apatinib, S1
Clinical Study IdentifierNCT04863430
SponsorPeking University
Last Modified on15 May 2021


Yes No Not Sure

Inclusion Criteria

Age: 18 to 70 years old, no gender limitation
Histopathological diagnosis of locally advanced, recurrent or metastatic HAS (pathological histomorphology and immunohistochemical diagnosis of AFP, sal-like 4(SALL4), Hep, glypican-3(GPC3), etc.)
Immunohistochemical(IHC) human epidermal growth factor receptor-2 (HER2) negative persons; HER2 positive is defined as IHC 3+ or IHC 2+ and fluorescence in situ hybridization(FISH)+, and FISH positive is defined as the ratio of HER2 gene copy number to chromosome 17 centromere(CEP17) signal number 2.0
According to the RECIST 1.1 standard, at least one measurable lesion (spiral CT scan 10mm)
ECOG performance status(PS): 0-2 points
The expected survival time is 3 months
The main organs are functionally normal, without serious blood, heart, lung, liver, kidney dysfunction and immune deficiency disease. The blood test meets the following requirements; (1) Routine blood examination, which must be met (no blood transfusion within 14 days)
WBC4.010^9/L; absolute neutrophil count(ANC) 2.010^9/L
PLT2.010^9/L; (2) The biochemical inspection must meet the following standards
BIL1.5 times the upper limit of normal (ULN)
Alanine aminotransferase(ALT) and aspartate aminotransferase(AST)2.5ULN; if there is liver metastasis, ALT and AST5ULN
serum Cr1.5ULN, endogenous creatinine clearance50ml/min (Cockcroft-Gault formula); (3) Occult blood in stool (-); (4) Urine routine is normal, or urine protein <(++), or 24-hour urine protein <1.0g
The coagulation function is normal, without active bleeding and thrombosis disease
International standardized ratio INR1.5ULN
Partial thromboplastin time APTT1.5ULN
Prothrombin time PT1.5ULN
Female subjects with fertility and male subjects whose partner is a female of childbearing age who need to take effective contraceptive measures during the study treatment period and at least 6 months after the last use of the study drug
Subjects voluntarily participate in this study and sign an informed consent form (ICF)
Those who have good compliance and can follow up as required by the plan

Exclusion Criteria

Various types of liver inflammatory diseases (especially hepatitis A, B, and C viral hepatitis active period) and other diseases that may produce AFP such as liver cirrhosis
Germ cell tumors
Have previously received any regimen of palliative chemotherapy for gastric cancer
Have previously received apatinib treatment
S-1 and/or oxaliplatin have been used in the past 6 months
Those who have hypertension and cannot be reduced to the normal range after treatment with antihypertensive drugs (shrinking Pressure>140mmHg or diastolic pressure>90mmHg)
Suffering from coronary heart disease 2 grade, arrhythmia corrected QT interval(QTc) interval prolonged male> 450ms, female;>470ms) and cardiac insufficiency
There are many factors that affect the absorption of oral drugs (such as inability to swallow, nausea and vomiting, chronic abdominal Diarrhea and intestinal obstruction, etc.)
Patients at risk of gastrointestinal bleeding or those with a history of gastrointestinal bleeding within 1 month
Abnormal blood coagulation function (INR>1.5ULN, activated partial thromboplastin time(APTT)>1.5ULN), those with bleeding tendency
Those with thrombotic diseases or receiving anticoagulant treatment
Those with peripheral sensitive neuropathy with dysfunction
Central nervous system metastasis
Pregnant or lactating women
Those who have participated in other clinical research in the past 30 days
Other patients considered by the treating physician to be unsuitable for inclusion
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note